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a b s t r a c t
The last ten years have seen rapid strides in the evolution of nonvitamin K oral antic-
oagulants (NOACs) for stroke prevention in patients with atrial ﬁbrillation (AF). For the
preparation of this consensus, a comprehensive literature search was performed and data
on available trials, subpopulation analyses, and case reports were analyzed. This Indian
consensus document intends to provide guidance on selecting the right NOAC for the right
patients by formulating expert opinions based on the available trials and Asian/Indian
subpopulation analyses of these trials. A section has been dedicated to the current evidence
of NOACs in the Asian population. Practical suggestions have been formulated in the
following clinical situations: (i) Dose recommendations of the NOACs in different clinical
scenarios; (ii) NOACs in patients with rheumatic heart disease (RHD); (iii) Monitoring
anticoagulant effect of the NOACs; (iv) Overdose of NOACs; (v) Antidotes to NOACs; (vi)
Treatment of hypertrophic cardiomyopathy (HCM) with AF using NOACs; (vii) NOACs dose in
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elderly, (viii) Switching between NOACs and vitamin K antagonists (VKA); (ix) Cardioversion
or ablation in NOAC-treated patients; (x) Planned/emergency surgical interventions in
patients currently on NOACs; (xi) Management of bleeding complications of NOACs; (xii)
Management of acute coronary syndrome (ACS) in AF with NOACs; (xiii) Management of
acute ischemic stroke while on NOACs.
# 2015 Published by Elsevier B.V. on behalf of Cardiological Society of India.
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Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia characterized by uncoordinated atrial activation
with subsequent deterioration of the atrial mechanical
function.1 It is an important risk factor for cardioembolic
stroke.2,3 Nonvalvular AF (NVAF) is associated with a 5-fold
increased risk of stroke,4 with stroke being more fatal and
disabling than in those without AF.5 The risk of stroke in AF
increased from 1.5% at 50–59 years of age to 23.5% at 80–89
years.2 Valvular AF on the other hand is associated with a 17-
fold increased risk of stroke.6 Importantly, in India, valvular AF
patients comprise not just those with mechanical heart valves,
but also those with rheumatic mitral stenosis. The group of
mild rheumatic valvular disease with AF patients needs to be
tested with NOACs for stroke prevention in AF, even though
21.8% of patients in RE-LY did have patients with mild to
moderate valvular heart disease with AF and were still
classiﬁed as NVAF.7 The prevalence of AF in the general
population in North America and Europe is 1–2%.8 The United
Kingdom (UK)-based West Birmingham Atrial Fibrillation
project showed a prevalence of 0.6% in the Indian subset.9
However, there is paucity of epidemiological data to determine
the true incidence and prevalence of AF in India. This paucity
seems to be addressed to some extent by the Indian Heart
Rhythm Society-Atrial Fibrillation (IHRS-AF) registry, REALIZE-
AF, and Indian subgroup analysis (unpublished) of pivotal
randomized controlled trials of the NOACs.10,11 The prevalence
of paroxysmal AF as reported in the RE-LY (Randomised
Evaluation of Long term anticoagulant therapY), REALIZE, and
IHRS-AF study was 38%, 43%, and 19.5%, respectively. Perma-
nent AF was reported in 18.6%, 34.3%, and 33.7% of participants
in the RE-LY, REALIZE, and IHRS-AF study, respectively.10
Every year, 20 million people worldwide experience a
stroke. In the Asia-Paciﬁc region, China and India have the
maximum number of deaths resulting from stroke.9 Approxi-
mately 15% of all strokes are associated with AF.10Table 1 – Definition of major and clinically relevant nonmajor 
Major risk factors 
Previous stroke, TIA, or systemic embolism, age >75 years He
<4
Hy
Fe
Va
TIA, transient ischemic attack; LV, left ventricle; EF, ejection fraction.
a Prior myocardial infarction, peripheral artery disease, aortic plaque.Importantly, longitudinal community-based studies con-
ducted worldwide have shown that there has been a steady
increase in AF incidence over the last two decades. This trend
is likely to continue over the next few decades with an ageing
population and higher occurrence of the associated risk
factors, including cardiac diseases. Despite major advances
in its management, AF still remains a signiﬁcant cause of
cardiovascular morbidity and mortality, especially that arising
from stroke and heart failure (HF).12
2. Stroke risk assessment
In patients with NVAF, prior stroke or transient ischemic
attack (TIA) is the strongest independent predictor of stroke.13
Heart failure, hypertension, increasing age, and diabetes
mellitus have consistently emerged as independent risk
factors for ischemic stroke associated with NVAF.14,15 Numer-
ous scoring schemes have been devised to predict stroke risk
based on the risk factors identiﬁed in nonwarfarin arms of
randomised clinical trial cohorts. However, these scores have
been developed nearly two decades ago and need to be
revisited with evidence from new epidemiological studies.
Two of the most commonly used stroke risk assessment tools
are discussed below.
The CHADS2 (congestive heart failure, hypertension, age
≥75 years, diabetes mellitus, prior stroke, or TIA or thrombo-
embolism [doubled]) score has been validated in numerous
cohorts.16,17 Though the scoring is simple, most researchers
now agree that it does not include many of the common stroke
risk factors and has several limitations and hence should not
be used in practice (Table 1).18,19
The CHA2DS2-VASc (congestive heart failure, hypertension,
age ≥75 [doubled], diabetes, stroke [doubled], vascular disease
[e.g., past myocardial infarction (MI), peripheral arterial
disease, or aortic atherosclerosis], age 65–74 years, and sex
category [female]) score are inclusive of the most common
stroke risk factors in everyday clinical practice. The CHADS2risk factors for stroke in nonvalvular atrial fibrillation.8
Clinically relevant nonmajor risk factors
art failure or moderate to severe LV systolic dysfunction (e.g., LV EF
0%)
pertension – Diabetes mellitus
male sex – Age 65–74 years
scular diseasea
Table 2 – Risk factors in the CHA2DS2-VASc score and the
adjusted stroke rate.20
Risk factor Score assigned
Congestive heart failure/left ventricle
dysfunction
1
Hypertension 1
Age >75 years 2
Diabetes mellitus 1
Stroke/TIA/thromboembolism 2
Vascular diseasea 1
Age 65–74 years 1
Sex category (i.e. female sex) 1
CHA2DS2-VASc score (total) Adjusted stroke rate (%/year)
0 0%
1 1.3%
2 2.2%
3 3.2%
4 4.0%
5 6.7%
6 9.8%
7 9.6%
8 6.7%
9 15.2%
TIA, transient ischemic attack; LV, left ventricle; EF, ejection
fraction.
a Prior myocardial infarction, peripheral artery disease, aortic
plaque.
Table 3 – Risk factors of the HAS-BLED scoring system.23
Risk factor Score assigned
Hypertensiona 1
Abnormal renal or liver function
(one point each)b
1 or 2
Stroke 1
Bleedingc 1
Labile INRd 1
Elderly (e.g. age >65 years) 1
Drugs or alcohol (1 point each)e 1
Maximum total score 9
INR, international normalized ratio.
a Hypertension' is deﬁned as systolic blood pressure >160 mmHg.
b Abnormal kidney function is deﬁned as the presence of chronic
dialysis or renal transplantation or serum creatinine ≥200 mmol/L.
Abnormal liver function is deﬁned as chronic hepatic disease (e.g.,
cirrhosis) or biochemical evidence of signiﬁcant hepatic derange-
ment (e.g., bilirubin 2 the upper limit of normal, in association
with aspartate aminotransferase/alanine aminotransferase/alka-
line phosphatase. 3 upper limit normal, etc.).
c Bleeding refers to previous bleeding history and/or predisposition
to bleeding, e.g. bleeding diathesis, anemia, etc.
d Labile INRs refers to unstable/high INRs or poor time in
therapeutic range (e.g. <60%).
e Drugs/alcohol use refers to concomitant use of drugs, such as
antiplatelet agents, nonsteroidal anti-inﬂammatory drugs, or
alcohol abuse, etc.
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followed by the comprehensive risk factor-based approach
using the CHA2DS2-VASc score.
6 Table 2 describes the scoring
pattern of the CHA2DS2-VASc score along with the adjusted
stroke rate per year. The net effect of the CHA2-DS2-VASc score
is to increase the proportion of appropriate AF patients for
whom anticoagulation is recommended.20
The overall goal of stroke risk assessment score is to
separate patients at 'true low-risk' and identify those who
need treatment. Individuals with a CHA2DS2-VASc score of 0
(age <65 years with 'lone AF' [individuals without clinical or
echocardiographical evidence of cardiopulmonary disease,
including hypertension]) and with a CHA2DS2-VASc score of 1
(female patients aged <65 years and with 'lone AF') can be
safely considered as 'truly low-risk' patients and antithrom-
botic therapy should not be considered.20 Antithrombotic
therapy should be considered for those with CHA2DS2-VASc
score of equal to or more than 1 in males and equal to or more
than 2 in females.
3. Bleeding risk assessment
Thromboprophylaxis with antithrombotic agents is associated
with an increased risk of bleeding and requires individual risk
assessment before initiation. Many of the risk factors for
bleeding overlap with the risk factors for stroke.21,22 Several
bleeding risk assessment tools are available but only three
have been derived and validated in patients with AF. These
include HEMORR2HAGES (hepatic or renal disease, ethanol
abuse, malignancy, older age [≥75 years], reduced platelet count
or function, rebleeding risk, hypertension [uncontrolled],anemia, genetic factors, excessive fall risk, and stroke), HAS-
BLED (hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile international normal-
ized ratio [INR], elderly [e.g., age >65 years, frailty, etc.], drugs/
alcohol concomitantly), and ATRIA (AnTicoagulation and Risk
factors In Atrial ﬁbrillation).20
The HAS-BLED score has been validated in multiple
cohorts. It has performed as good as (sometimes better than)
the more complex HEMORR2HAGES and outperformed the less
practical ATRIA score in predicting clinically relevant bleed-
ing.23,24 A high HAS-BLED score (≥3) is predictive of major
bleeding during bridging of chronic anticoagulant therapy.25 It
is recommended to use HAS-BLED score for the assessment of
oral anticoagulant-related bleeding risk in clinical practice.
Table 3 provides the details of the HAS-BLED scoring system.
The CHA2DS2-VASc and the HAS-BLED scores have been
derived and validated mostly in the Western population. A
meta-analysis identiﬁed different set of risk factors that are
associated with stroke in the Western and the Asian popula-
tion.26,27 Another meta-analysis found that the incidence of
intracerebral hemorrhage is the highest among the Asians.28
Although validation of these scores is available in a Chinese
population, it is recommended to validate both the CHA2DS2-
VASc and the HAS-BLEED scores in the Indian population for
improved management strategies for stroke prevention.29
4. Oral antithrombotic agents
4.1. Vitamin K antagonist (VKA)
Until 2009, vitamin K antagonist (VKA) (such as warfarin)
was the only class of oral anticoagulant approved for the
Table 4 – Food and drug interactions with warfarin.
Potentiate the effect of warfarin Inhibit the effect
of warfarin
Acetaminophen Mercaptopurine
Alcohol (if concomitant liver disease) Mesalamine
Fenoﬁbrate Ribavirin
Mango Trazodone
Miconazole vaginal suppositories Azathioprine
Quilinggao Bosentan
Amoxicillin/clavulanate Ginseng
Azithromycin Ritonavir
Celecoxib Sulfasalazine
Clarithromycin Terbinaﬁne
Danshen Ubidicarenone
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that inhibits vitamin K epoxide reductase responsible for the
cyclic interconversion of vitamin K and vitamin K epoxide.
Vitamin K is an essential cofactor for the carboxylation of
coagulation factors II, VII, IX, and X, and therefore, their
biological activation. Antagonism of vitamin K reduces the rate
at which these factors are produced by the liver, thereby
creating a state of anticoagulation.30
A meta-analysis of data from six randomized clinical trials
that compared a VKA with placebo or control found that
adjusted-dose warfarin reduced the relative risk (RR) of stroke
by 64% (95% conﬁdence interval [CI] 49–74) versus placebo or
control. The relative risk reduction for ischemic stroke with
adjusted-dose warfarin was 67% (95% CI 54–77) while the
reduction in all-cause mortality was 26% (95% CI 3–43).31 The
Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA)
study showed that treatment with VKA (target INR of 2–3) was
superior to aspirin 75 mg daily in reducing the primary endpoint
of fatal or disabling stroke, intracranial hemorrhage (ICH), or
clinically signiﬁcant arterial embolism by 52%. The risk of
major hemorrhage was comparable between the two groups.32
The target INR should protect from ischemic stroke as well
as hemorrhagic complications. Many studies and meta-
analyses have reported the risk of stroke and/or major
bleeding events in relation to INR, or the time spent in
therapeutic range (TTR).33–35 It is evident that the risk of
ischemic stroke with insufﬁcient warfarin anticoagulation
(INR < 2) and that of bleeding with over anticoagulation
(INR > 3) is signiﬁcantly higher relative to patients with NVAF
maintained within an INR of 2–3. For the primary prevention
of stroke in patients above 75 years, a target INR of 2 (range
1.6–2.5) is recommended while a target of 2.5 (range 2–3) is
favorable for patients below 75 years (Fig. 1).1,36
The effectiveness and safety of warfarin treatment depends
on the extent of time spent in the recommended INR range. A
meta-analysis found that patients receiving warfarin spent
61% of time within, 13% of time above, and 26% of time below
the therapeutic range (INR range 2–3). Gallagher et al.
evaluated the association between TTR, when on warfarin
anticoagulation treatment, and the risk of stroke andVKA therapy has 
several  
limitaons  th at 
make it di ﬃcult 
to use in 
prac ce
Unpred ictable 
response
Narrow 
therapeuc 
window 
(INR range 2-3 )
Roune 
coagul aon  
monitoring
Slow ons et/oﬀset 
of acon
Intrac ranial 
bleeding
Numerous food & 
drug interacons
Warfar in 
resistance  CYP 
2C9, VKORC1 
genec 
polymorphisms
Fig. 1 – Limitations of vitamin K therapy.mortality.37 The average time spent in the therapeutic range
was 63.1%. Reduction in stroke was the highest (79%) when the
patients spent at least 70% of time within the therapeutic
range when compared to patients with ≤30% time in the
recommended range. Signiﬁcant reduction in the risk of stroke
was observed when time spent in therapeutic range was more
than 61% as compared to those who did not receive any
antithrombotic therapy. The risk of mortality was reduced by
81% in warfarin users who spent at least 70% of time in the
therapeutic range.
Because warfarin undergoes hepatic metabolism and is
highly protein bound, it is particularly prone to drug interac-
tions. Warfarin has two active isomers, the S-isomer being 2–4
times more potent than the R-isomer. The S-isomer is
metabolized primarily by the cytochrome P450 2C9 (CYP2C9)
and the R-isomer is metabolized by cytochrome P450 1A2
and 3A4 isozymes. The effect on INR is typically observed
within 3–5 days for drugs with short half-lives and is delayed
further for drugs with longer half-lives. Some important
interactions of warfarin are listed in Table 4. In addition,
warfarin has several other limitations and challenges, such as
a narrow therapeutic window, increased risk of bleeding
including ICH, frequent intensive INR monitoring, and dose
adjustment.38 Some of the limitations of warfarin therapy areFluorouracil Green tea
Fluvastatin Furosemide
Fluvoxamine Propofol
Gemcitabine Furosemide
Grapefruit juice
Interferon
Levamisole/ﬂuorouracil
Levoﬂoxacin
Paclitaxel
Paracetamol
Ritonavir
Ropinirole
Tolterodine
Tramadol
Troglitazone
Acarbose
Amiodarone induced toxicosis
Amoxicillin
Chloramphenicol
Danazol
Miconazole topical gel
Oﬂoxacin
Trastuzumab
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include high coefﬁcient of interlab variation in INR estimation;
INR is not reﬂective of monthly or long-term control (TTR as
measured by the Rosendaal method along with Finn method
may be estimated for more appropriate control); certain drugs
like amiodarone may themselves affect INR and thus,
interpretation of the patient's INR in those taking co-
medications becomes difﬁcult; patients with INR between 2
and 3 can still bleed or have a stroke.39,40
Warfarin-related nephropathy is a newly described entity
in those with an acutely increased INR of more than 3 soon
after the initiation of warfarin. This, if conﬁrmed, is especially
serious in patients with chronic kidney disease (CKD) in whom
it is more often associated with an unexplained acute increase
in serum creatinine and an accelerated progression of CKD. In
4006 patients with CKD and INR exceeding 3, the one-year
mortality was 31.1% compared with 18.9% without warfarin-
related nephropathy. Hence, the INR should be kept below 3 in
all patients soon after starting warfarin, but essentially in
those with CKD or those who use antithrombin inhibitors.41
Even with the advent of NOACs, in India, there will always
be a role for the relatively cheaper VKAs due to the cost factor.
VKAs are still the preferred drug in situations including, but
not limited to, those AF patients on mechanical heart valves or
those with creatinine clearance <15 ml/min.
4.2. Nonvitamin K oral anticoagulants (NOACs)
The NOACs fall into two major categories: direct thrombin
(factor IIa) inhibitors (dabigatran) and direct factor Xa
inhibitors (rivaroxaban, apixaban, and edoxaban). As com-
pared to warfarin, these NOACs have a predictable pharmaco-
kinetic proﬁle and fewer food-drug and drug-drug interactions,
and do not require routine anticoagulant monitoring.21
Following rigorous phase III clinical trials, dabigatran received
the United States Food and Drug Administration (US FDA)
approval to prevent stroke in patients with NVAF in 2010. This
was followed by rivaroxaban approval in 2011 and apixaban
approval in 2012. All the three drugs are also approved in
Europe. Edoxaban received the US FDA approval in 2015 and an
application for the marketing authorization has been recently
submitted to the European Medicines Agency (EMA).
4.2.1. Dabigatran
Dabigatran etexilate is an oral prodrug that is rapidly converted
by serum esterase-mediated hydrolysis to dabigatran, a potent,Table 5 – Summary of pharmacokinetic parameters of NOACs.
Dabigatran
(Pradaxa®)43
Rivaroxaban (Xarelt
Bioavailability 3–7% 66% without food; almo
with food
Time for peak effect 2–3 h 2–4 h 
Plasma half-life 12–17 h 5–13 h 
Metabolism Via P-gp
transporter
Via CYP450 and P-gp tra
Clearance nonrenal/renal 20%/80% 73%/27% direct competitive inhibitor of thrombin.42 A summary of the
pharmacokinetics of dabigatran has been presented in Table 5.43
Dabigatran offers an advantage over indirect thrombin
inhibitors like heparin, as it inhibits both free and ﬁbrin-bound
thrombin. The reversible binding of dabigatran is comparable
to injectable direct thrombin inhibitor (DTI), bivalirudin. DTIs
have an antiplatelet effect as well due to reduced thrombin-
mediated activation of platelets. They produce a more
predictable anticoagulant response than heparin, as they do
not bind to plasma proteins and lack immune-mediated
thrombocytopenia.44–46
The pivotal RE-LY trial compared two blinded doses of
dabigatran etexilate (110 mg [D110] or 150 mg [D150] BID, twice
daily) with an open-label, adjusted-dose of warfarin.7 The
study design and baseline characteristics have been elaborat-
ed in Table 6.
The D150 arm was superior ( p < 0.001) while the D110 arm
was noninferior ( p < 0.001) versus the warfarin arm for the
primary efﬁcacy endpoint of stroke or systemic embolism in
the trial. Both doses of dabigatran reduced the annual rate of
hemorrhagic stroke signiﬁcantly. The annual rate of major
bleeding was signiﬁcantly lower with D110. Intracranial
bleeding in the dabigatran group was observed at less than
one-third the rate observed with warfarin, without a reduction
in efﬁcacy against ischemic stroke. Gastrointestinal (GI)
bleeding was the most important adverse effect of the higher
dose of dabigatran. A higher rate of MI was observed with both
doses of dabigatran. However, the difference was not statisti-
cally signiﬁcant when compared to warfarin. Overall, dabiga-
tran 110 mg BID was noninferior to warfarin but had lower
rates of major bleeding episodes and dabigatran 150 mg BID
was superior to warfarin but had similar rates of major
bleeding episodes.7 The efﬁcacy and safety outcomes of the
trial have been elucidated in Table 7.
In a subgroup analysis of the RE-LY trial for treatment effects,
dabigatran was compared with warfarin for secondary preven-
tion in patients with prior stroke or TIA; both doses of dabigatran
were associated with lower rates of stroke or systemic embolism
than warfarin (RR 0.84 for D110 and 0.75 for D150).47A signiﬁcant
treatment-by-age interaction was also observed. D110 was
associated with a lower risk of major bleeding in patients below
75 years of age (1.89% versus 3.04%; p < 0.001) and with similar
risk in those aged 75 years and above (4.43% versus 4.37%;
p = 0.89; p for interaction < 0.001). Similarly, D150 was associated
with a lower risk of major bleeding in those aged <75 years
(2.12% versus 3.04%; p < 0.001) and showed a trend towardso®)55,56 Apixaban (Eliquis®)62 Edoxaban (SAVYASA)64
st 100% 50% 62%
3–4 h 1–2 h
12 h 10–14 h
nsporter Via CYP450 and P-gp
transporter
Via CYP450 and P-gp
transporter
50%/50% 65%/35%
Table 6 – Study design and baseline characteristics of Phase III pivotal trial with NOACs.
Dabigatran7 Rivaroxaban58 Apixaban62 Edoxaban65
Study acronym RE-LY ROCKET-AF ARISTOLE ENGAGE AFTIMI-48
Study design Randomized, open-
label
Randomized, double
blind
Randomized double
blind
Randomized double blind
No. of patients 14,264 18,201 21,105
Follow-up period, yrs 2 1.9 1.8 2.8
Randomized groups Dose-adjusted
warfarin (W) versus
dabigatran 110 mg
BID (D110),
dabigatran 150 mg
BID (D150)
Dose-adjusted
warfarin (W) versus
rivaroxaban 20 mg
OD (R20)
Dose-adjusted
warfarin (W) versus
apixaban 5 mg BID
(A5)
Dose-adjusted warfarin
(W) versus Low-dose
edoxaban 30 mg OD
High-dose edoxaban
60 mg OD
Dose adjustment None 15 mg OD in CrCl- 30
to 49 ml/min
2.5 mg BID if (any two
of) age ≥80 years,
body weight <60 kg,
serum creatinine
level ≥1.5 mg/dl
Dose was halved if
estimated CrCl 30–50 ml/
min, body weight ≤60 kg,
or the concomitant
potent P-gp inhibitors
(verapamil or quinidine)
Age, yrs 71.5  8.7
(mean  SD)
73 (65–78)
[median
(interquartile range)]
70 (63–76)
[median
(interquartile range)]
72 (64–78)
[median (interquartile
range)]
Male, sex % 63.6 61.3 64.5 62.5
CHADS2 score (Mean) 2.1 3.5 2.1 2.8
RE-LY, Randomized Evaluation of Long term anticoagulant therapy; ROCKET-AF, Rivaroxaban Once-daily oral direct factor Xa inhibition
Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation; ARISTOLE, Apixaban for Reduction In
STroke and Other ThromboemboLic Events in atrial ﬁbrillation; ENGAGE AF-TIMI 48, Effective Anticoagulation with Factor Xa Next Generation
in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48; BID, twice daily; OD, once daily; CrCl, Creatinine clearance; P-gp, P-glycoprotein.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4S18higher risk of major bleeding in those aged ≥75 years (5.10%
versus 4.37%; p = 0.07; p for interaction <0.001).48
Real-world evidence on the safety and effectiveness of
dabigatran versus warfarin is available for a total of more than
250,000 patients; more than 118,000 of these were new users of
dabigatran who were propensity-score matched or propensity-
score weighed to new users of warfarin.49–53 Dabigatran was
associated with a reduced risk of ischemic stroke (Hazard ratio
HR, 0.80; 95% CI, 0.67–0.96), ICH (HR, 0.34; 95% CI, 0.26–0.46), and
death (HR, 0.86; 95% CI, 0.77–0.96), compared with warfarin.
Rates of major bleeding (HR, 0.97; 95% CI, 0.88–1.07) and MI (HR,
0.92; 95% CI, 0.78–1.08) were similar with both dabigatran and
warfarin; however, the risk for major GI bleeding (HR, 1.28; 95%
CI, 1.14–1.44) was increased with dabigatran versus warfarin.49
Importantly, these ﬁndings from large populations in clinical
practice were consistent with the favorable safety and efﬁcacy
proﬁle of dabigatran indicated in the pivotal RE-LY study.
Factor Xa inhibitors: Factor Xa (FXa) is an attractive target for
novel anticoagulants as it acts at the convergence point of
the intrinsic and extrinsic coagulation pathways. One mole-
cule of FXa catalyses the formation of 1000 thrombin
molecules together with factor Va (as the prothrombinase
complex). Inhibition of FXa activity blocks the ampliﬁcation of
thrombin generation, thereby limiting thrombin-mediated
activation of coagulation and platelets without affecting the
existing thrombin levels.
4.2.2. Rivaroxaban
Rivaroxaban is a highly selective, reversible direct oral FXa
inhibitor.54 It is rapidly absorbed after oral administration and
attains maximum plasma concentration after 2–4 h. The phar-
macokinetic parameters of rivaroxaban have been elucidatedin Table 5 and the prominent Drug interactions of Rivaroxaban
have been detailed in Table 8.55,56
The Rivaroxaban Once daily oral direct factor Xa inhibition
compared with vitamin K antagonism for prevention of stroke
and Embolism Trial in Atrial Fibrillation (ROCKET-AF) was a
double-blind, double-dummy study conducted in 45 countries
worldwide. The study design and patient characteristics of
ROCKET-AF have been detailed in Table 6.57
The trial results showed that rivaroxaban was noninferior to
warfarin in both the primary efﬁcacy endpoint of stroke and
systemic embolism prevention ( p < 0.001 for noninferiority) as
well as the safety endpoint of major and clinically relevant
nonmajor bleeding. The trial results have been elucidated in
detail in Table 7. Major bleeding from a GI site was signiﬁcantly
higher in the rivaroxaban group (3.2%), as compared to the
warfarin group (2.2%, p < 0.001). Though there was no signiﬁcant
difference in the rates of major and clinically relevant nonmajor
bleeding between the two groups, intracranial bleeding and
fatal bleeding occurred less frequently with rivaroxaban.58
A subgroup of patients (20.7% of the enrolled population)
with moderate renal impairment (Creatinine clearance, CrCl
30–49 ml/min) received a lower dose of rivaroxaban. For
patients with moderate renal impairment, the rate of stroke
and systemic embolism, major and clinically nonrelevant
bleeding events were higher than those with CrCl ≥50 ml/min.
Comparative treatment effects for rivaroxaban versus warfa-
rin were similar for all major outcomes, including bleeding
events, for those with and without renal impairment. GI
bleeding was more frequent than warfarin in this subgroup of
patients (4.1% versus 2.6% for warfarin, p = 0.02).59
A subgroup analysis of ROCKET-AF investigated the efﬁcacy
and safety of rivaroxaban in patients aged ≥75 years and in
Table 7 – Summary of efficacy and safety outcomes of NOACs.
Outcome
(% per yr)
Dabigatran7
(RE-LY)
Rivaroxaban58
(ROCKET-AF)
Apixaban62
(ARISTOLE)
Edoxaban65
(ENGAGE AF TIMI-48)
W
(n = 6022)
D110
(n = 6015)
RR, 95% CI,
p value
D150
(n = 6076)
RR, 95% CI,
p value
W
(n = 7133)
R20
(n = 7131)
HR (95% CI,
p value)
W
(n = 9081)
A5
(n = 9120)
HR (95% CI,
p value)
W
(n = 7035)
E30
(n = 7034)
HR (95% CI,
p value)
E60
(n = 7035)
HR (95% CI,
p value)
Stroke or
systemic
embolism
1.71 1.54 (0.90; 0.74–1.10;
p < 0.001; NI)
1.11 (0.65; 0.52–0.81;
p < 0.001 (NI, Sup)
2.4 2.1 (0.88; 0.75–1.03;
p < 0.001; NI)
1.6 1.27 (0.79; 0.66–0.95;
p < 0.001; NI,
p = 0.01; Sup)
1.50 1.61 (1.07; 0.87–1.31;
p = 0.005; NI)
1.18 (0.79; 0.63–0.99;
p < 0.001; NI)
Ischemic stroke 1.21 1.34 (1.11; 0.88–1.39;
p = 0.35)
0.92 (0.76; 0.59–0.97;
p = 0.03)
1.42 1.34 (0.94; 0.75–1.17;
p = 0.581)
1.05 0.97 (0.92; 0.74–1.13;
p = 0.42)
1.25 1.77 (1.41; 1.19–1.67;
p < 0.001)
1.25 (1.00; 0.83–1.19;
p = 0.97)
Hemorrhagic
stroke
0.38 0.12 (0.31; 0.17–0.56;
p < 0.001)
0.10 (0.26; 0.14–0.49;
p < 0.001)
0.44 0.26 (0.59; 0.37–0.93;
p = 0.024)
0.47 0.24 (0.51; 0.35–0.75;
p < 0.001)
0.47 0.16 (0.33; 0.22–0.50;
p < 0.001)
0.26 (0.54; 0.38–0.77;
p < 0.001)
Major bleeding 3.57 2.87 (0.80; 0.70–0.93;
p = 0.003)
3.32 (0.93; 0.81–1.07;
p = 0.31)
3.4 3.6 (1.04; 0.90–1.20;
p = 0.58)
3.09 2.13 (0.69; 0.60–0.80;
p < 0.001)
3.43 1.61 (0.47; 0.41–0.55;
p < 0.001)
2.75 (0.80; 0.71–0.91;
p < 0.001)
Intracranial
bleeding
0.76 0.23 (0.30;0.19–0.45;
p < 0.001)
0.32; 0.41 (0.28–0.60)
p < 0.001
0.7 0.5 (0.67; 0.47–0.93
p = 0.02)
0.80 0.33 (0.42; 0.30–0.58;
p < 0.001)
0.85 0.26 (0.30; 0.21–0.43;
p < 0.001)
0.39 (0.47; 0.34–0.63;
p < 0.001)
Gastrointestinal
bleeding
1.07 1.15; 1.08 (0.85–1.38;
p = 0.52
1.56; 1.48 (1.18–1.85;
p = 0.001
2.2 3.2 ( p < 0.001) 0.86 0.76 (0.89; 0.70–1.15;
p = 0.37)
1.23 0.82 (0.67; 0.53–0.83;
p < 0.001)
1.51 (1.23; 1.02–1.50;
p = 0.03)
Myocardial
infarction
0.64 0.82 (1.29; 0.96–1.75;
p = 0.09)
0.81 (1.27; 0.94–1.71;
p = 0.12)
1.1 0.9 (0.81; 0.63–1.06;
p = 0.12)
0.61 0.53 (0.88; 0.66–1.17;
p = 0.37)
0.75 0.70 (0.94; 0.74–1.19;
p = 0.60)
0.89 (1.19; 0.95–1.49;
p = 0.13)
All cause
mortality
4.13 3.75 (0.91; 0.80–1.03;
p = 0.13)
3.64 (0.88; 0.77–1.00;
p = 0.051)
2.2 1.9 (0.85; 0.70–1.02;
p = 0.07)
3.94 3.52 (0.89, 0.80–0.99;
p = 0.047)
4.35 3.80 (0.87; 0.79–0.96;
p = 0.006)
3.99 (0.92; 0.83–1.01;
p = 0.08)
Net clinical
beneﬁt
outcome
7.91 7.34 (0.92; 0.84–1.01;
p = 0.09)
7.11 (0.90; 0.82–0.99;
p = 0.02)
– – 7.20 6.13 (0.85; 0.78–0.92;
p < 0.001)
8.11 6.79 (0.83; 0.77–0.90;
p < 0.001)
7.26 (0.89; 0.83–0.96;
p = 0.003)
W, dose-adjusted warfarin; D110, dabigatran 110 mg twice daily; D150, dabigatran 150 mg twice daily; R20, rivaroxaban 20 mg once daily; A5, apixaban 5 mg twice daily; E30, edoxaban 30 mg once daily;
E60, edoxaban 60 mg once daily.
i
 n
 d
 i
 a
 n
 h
 e
 a
 r
 t
 j
 o
 u
 r
 n
 a
 l
 6
 7
 (
 2
 0
 1
 5
 )
 s
 1
 3
 –
 s
 3
 4
 
S
19
Table 8 – Drug interactions with NOACs.
, contraindicated; , dose reduction required; , consider dose reduction if another yellow present; , no dose adjustment.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4S20those aged <75 years. There was no signiﬁcant interaction
between treatment and age for the primary outcome of stroke
or systemic embolism ( p = 0.31) or for major bleeding
( p = 0.34). Clinically relevant nonmajor bleeding was signiﬁ-
cantly higher for patients aged ≥75 years compared with
patients aged <75 years ( p = 0.01).60
One real-world study that included atrial ﬁbrillation
patients compared 3654 rivaroxaban-treated patients with
14,616 matched warfarin patients. Rivaroxaban was associated
with similar rates of major bleeding (HR, 1.08; 95% CI: 0.71–
1.64), ICH (HR, 1.17; 95% CI: 0.66–2.05), and GI bleeding (HR, 1.27;
95% CI: 0.99–1.63) when compared with warfarin. Rates of
composite stroke and systemic embolism for rivaroxaban and
warfarin were also similar (HR, 0.77; 95% CI: 0.55–1.09).61
4.2.3. Apixaban
Apixaban is a selective, reversible direct oral inhibitor of factor
Xa. The important pharmacokinetic parameters have been
detailed in Table 5 while the common drug interactions with
apixaban have been detailed in Table 8.62
The Apixaban for Reduction In STroke and Other Throm-
boemboLic Events in atrial ﬁbrillation (ARISTOTLE) trial
included patients with NVAF and at least one of the following
risk factors for stroke: age of at least 75 years, previous history
of stroke, TIA, or systemic embolism, symptomatic heart
failure within the previous 3 months or left ventricular
ejection fraction of no more than 40%; diabetes mellitus; orhypertension. The ARISTOTLE study design and the char-
acteristics of the enrolled study patients have been detailed in
Table 6.62 It is important to note that 26.4% of patients had mild
to moderate valvular heart disease along with AF in the
ARISTOTLE study.62
The ARISTOTLE trial proved the superiority of apixaban
over dose-adjusted warfarin in preventing stroke and systemic
embolism ( p < 0.01 for superiority). The major efﬁcacy and
safety results of ARISTOTLE have been detailed in Table 7. The
protocol of apixaban deﬁned major bleeding as clinically overt
bleeding accompanied by a decrease in the hemoglobin level of
at least 2 g/dl or more over a 24-hour period, along with the
other clauses of the deﬁnition as per the International Society
on Thrombosis and Haemostasis (ISTH). However, it remains
unclear whether the ﬁnal results capture the major bleeding
using this deﬁnition or not. Rates of hemorrhagic stroke and
intracranial bleeding were signiﬁcantly lower ( p < 0.001 for
superiority) in patients treated with apixaban than with
warfarin. GI bleeding was similar between the treatment
arms. There was no signiﬁcant difference in the incidence of
ischemic stroke. A predeﬁned subgroup analysis in the
ARISTOTLE trial found no signiﬁcant interaction between
the TTR with warfarin treatment and any of the other efﬁcacy
or safety outcomes. However, a signiﬁcant interaction
( p = 0.003) was observed for major bleeding between diabetics
(3.0% per year) and nondiabetics (1.9% per year) when treated
with apixaban. Thus, in patients with NVAF and increased risk
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4 S21of stroke, apixaban was superior to warfarin in preventing
stroke or systemic embolism, caused less bleeding, and
resulted in lower mortality.62 The effect of apixaban in
preventing stroke and reducing mortality was signiﬁcantly
better than warfarin across all age groups, and was associated
with less major bleeding, less total bleeding, and less
intracranial hemorrhage regardless of age ( p interaction
>0.11 for all).63 However, the ARISTOTLE study did not allow
patients to be on dual antiplatelet therapy and the predeﬁned
dosing in the study probably ensured that patients with a
higher risk of bleeding got a lower dose (2.5 BID).
4.2.4. Edoxaban
Edoxaban is also an oral, selective inhibitor of Factor Xa. The
pharmacokinetics of edoxaban has been detailed in Table 5
and important drug interactions of Edoxaban are tabled in
Table 8.64
The Effective Anticoagulation with Factor Xa Next Gener-
ation in Atrial Fibrillation–Thrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) was a double-blind,
double-dummy trial that compared two doses of edoxaban
(60 mg [E60] and 30 mg [E30] once daily) with warfarin (target
INR 2.0–3.0). The study characteristics have been detailed in
Table 6.65 Both once-daily regimens of edoxaban were
noninferior ( p < 0.005 for E30 group and p < 0.001 for E60
group for noninferiority) to warfarin with respect to the
prevention of stroke or systemic embolism and were
associated with signiﬁcantly lower rates of bleeding and
death from cardiovascular causes. The key efﬁcacy and safety
results of the ENGAGE-AF TIMI48 study have been detailed
in Table 7.
4.3. Efﬁcacy and safety of NOACs versus warfarin in
NVAF
The NOACs have been evaluated and tested extensively in
large trials for their efﬁcacy and safety, including ‘‘real life’’
follow-up data. The pivotal randomized trials were mostly
designed as noninferiority studies and thus powered to show
that NOACs are at least as good as warfarin in the prevention of
stroke in AF. It is evident that dabigatran 150 mg BID and
apixaban 5 mg BID were superior to warfarin in reducing
stroke (or systemic embolism). Dabigatran reduced stroke (or
systemic embolism) by 35% and apixaban reduced it by 21%.
More importantly, only dabigatran 150 mg BID showed a
signiﬁcant reduction in the incidence of ischemic stroke. All
NOACs reduced the risk of hemorrhagic stroke when com-
pared with warfarin (Fig. 2). In the ROCKET-AF study, patients
(n = 1474) with a CrCl of 30–49 ml/min received a lower dose of
rivaroxaban 15 mg OD. In the ARISTOTLE study, few patients
(n = 428) received half the dose of apixaban (2.5 mg BID). In the
ENGAGE AF-TIMI 48 study, the dose of edoxaban was reduced
from 60 mg OD to 30 mg OD (n = 1787) in the high-dose arm or
from 30 mg OD to 15 mg OD (n = 1784) in the low-dose arm.
Thus, all three studies included a dose-adjusted subset of
population in the primary efﬁcacy and safety analysis that
may add to some bias in the endpoints. Dabigatran was
also evaluated at a lower dose; however, no further dose
adjustments were made and all patients in each subgroup
showed comparable baseline characteristics.Currently, there are no head to head trials comparing the
efﬁcacy of NOACs. Several authors have performed meta-
analysis of these trials. Differences in trial designs along with
the deﬁnition of safety and efﬁcacy endpoints pose a challenge
to the meta-analysis of these trials. A systematic review
evaluated the results of the NOAC versus warfarin trials (RE-
LY, ROCKET-AF, and ARISTOTLE) and concluded that overall
mortality was decreased in patients with AF receiving NOACs
(risk difference estimated to be 8 [95% CI 3–11] fewer deaths per
1000 patients, RR 0.88, 95% CI 0.82–0.96).66 In the meta-analysis
that also included ENGAGE AF-TIMI, all-cause mortality was
also signiﬁcantly reduced with NOACs (2022 events in 29,292
patients [6.9%]) versus warfarin (2245 events in 29,221 patients
[7.7%], RR 0.90, 95% CI 0.85–0.95, p = 0.0003).67 In a meta-
analysis of 50,578 patients from three randomized trials
(RE-LY, ROCKET-AF, and ARISTOTLE), NOACs were found to
signiﬁcantly decrease the rate of stroke or systemic embolism
as well lower the rates of intracranial bleeding. NOACs were
associated with a signiﬁcant 18% reduction in the composite
of stroke or systemic embolism when compared to warfarin
(2.8% versus 3.5%, odds ratio [OR] 0.82, 95% CI [0.74–0.91],
p < 0.001; I2 = 0% for heterogeneity; p = 0.62). All-cause mortal-
ity (6.0% versus 6.3%, OR 0.88, 95% CI [0.82–0.95], p = 0.001;
I2 = 0% for heterogeneity; p = 0.76) and rate of hemorrhagic
stroke (0.3% versus 0.8%, OR 0.79, 95% CI [0.71–0.88], p < 0.001;
I2 = 59% for heterogeneity; p = 0.09) were signiﬁcantly lower for
NOACs as compared to warfarin. NOACs were associated with
lower rates of intracranial bleeding (0.6% versus 1.3%,
p < 0.001) and higher rates of GI bleeding (2.3% versus 1.3%,
p = 0.036); however, heterogeneity among the trials was high
for these endpoints. There was no difference in the rates
of myocardial infarction.68 Yet another meta-analysis found
that the risk of intracranial bleeding with NOACs was lower
than with warfarin (RR 0.46; 95% CI 0.33–0.65) but the risk
of nonhemorrhagic stroke and systemic embolism was
comparable to warfarin (RR 0.93; 95% CI 0.83–1.04).69 This
meta-analysis also observed the inﬂuence of geography on
treatment outcomes. Asian patients experienced signiﬁcantly
fewer strokes and systemic embolism in RE-LY and ARISTOTLE
studies in comparison to non-Europeans, whereas no signiﬁ-
cant difference was observed in ROCKET-AF.
4.4. NOACs in Asian population
The Asian subgroup analysis for the major Phase III trials of
dabigatran, apixaban, and edoxaban is detailed in Table 9 with
respect to the major efﬁcacy and safety endpoints.65,70–72
Further analysis of the RE-LY trial revealed that the rates of
bleeding outcomes (major, GI major, life-threatening major,
minor, total, intracranial, and hemorrhagic stroke) when on
warfarin were numerically higher in the Asian subjects than
in non-Asians. A signiﬁcant interaction ( p = 0.008) between
treatment effect and the geographical region was observed
when comparing D150 versus warfarin in Asians and non-
Asians.73A previous report on AF patients treated with warfarin
found a 4-fold higher HR for ICH in Asians compared with the
whites.74 A Japanese subgroup analysis of ROCKET-AF trial is
also available and it showed noninferiority of rivaroxaban to
warfarin in the primary efﬁcacy endpoint of stroke and systemic
embolism (HR for rivaroxaban 0.49, 95% CI 0.24–1.00) and
Fig. 2 – Efficacy and safety of NOACs.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4S22demonstrated no signiﬁcant differences in the incidence of
major hemorrhage between the treatment groups.75
4.5.. Gastrointestinal bleeding with NOACs
In individual studies, major GI bleeding risk was signiﬁcantly
increased with rivaroxaban, edoxaban (higher dose), and
dabigatran (higher dose), albeit there was no increase in GITable 9 – Summary of efficacy and safety outcomes of NOACs 
RR (95% CI) Dabigatran (RE-LY) Apixaban (ARISTOLE
D15073
(n = 2782)
D11073
(n = 2782)
Study using 5 mgb
(n = 1993)62
Stroke or systemic
embolism
0.45
(0.28–0.72)
0.81
(0.54–1.21)
0.74
(0.50–1.10)
Major bleeding 0.57
(0.38–0.84)
0.57
(0.39–0.80)
0.53
(0.35–0.80)
Intracranial
bleeding
0.20
(0.07–0.60)
0.41
(0.27–0.63)
0.36
(0.18–0.71)
All-cause death 0.90
(0.78–1.04)
0.98
(0.73–1.32)
1.02
(0.70–1.50)
a From phase III trials.
b Dose adjustments were made in all trials on the basis of renal funct
administration of other drugs.
c Hazard ratio not provided. Abbreviations: NA, not available; RR, relativmajor bleeds with dabigatran (lower dose) and apixaban. In a
meta-analysis by Ruff et al., all NOACs together increased GI
major bleeding (OR 1.25, 95% CI 1.01–1.55; p = 0.04).67 Upon
searching for MedDRA preferred terms for nonadjudicated GI
bleeding AEs as reported in www.clinicaltrials.gov, similar or
higher rates of GI bleeding events were observed with standard
dose NOACs versus warfarin.76 Table 10 describes the GI
bleeding incidences in NOAC studies.in Asian population subgroup analysisa
) Edoxaban
Engage AF-TIMI 48
Rivaroxaban
ROCKET-AF
30 mg once dailyb
(n = 3383)65
60 mg once dailyb
(n = 3383)65
20 mg once dailyb
(n = 932)75
Annualized rate
1.83% versus
2.37% (Warfarin)
Annualized rate
2.43% versus
2.37% (Warfarin)
0.76
(0.42–1.37)
Annualized rate
1.87% versus
4.12% (Warfarin)c
Annualized rate
3.51% versus
4.12% (Warfarin)c
0.63
(0.37–1.09)
NA NA 0.23
(0.08–0.68)
NA NA 0.70
(0.40–1.25)
ion, and in some trials on the basis of body mass and concurrent
e risk.
Table 10 – Nonadjudicated GI bleeding with NOACs.67,76
Study Warfarin NOAC standard
dose
NOAC
low dose
RE-LY 1.37 1.93 1.42
ROCKET-AF 2.68 3.52 –
ARISTOTLE 1.59 1.93 –
ENGAGE-AF 3.19 3.28 2.33
All values in % patients per year.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4 S234.6. NOACs in elderly patients (>75 years)
A meta-analysis by Sardar P and colleagues suggests that risk
of major or clinically relevant bleeding was not signiﬁcantly
different between NOACs and conventional therapy in elderly
adults. In AF trials, NOACs were more effective than
conventional therapy in prevention of stroke or systemic
embolism in an elderly population with AF. Hence, the group
recommends that age should not be a limiting factor for use of
NOACs.77
4.7. NOACs in rheumatic heart disease
NOACs are approved for treatment of nonvalvular AF. Patients
with valvular AF, i.e., patients with mechanical prosthetic
heart valves or with severe valve disorder causing AF were
excluded from all NOAC trials. Atrial ﬁbrillation in patients
with valvular problems other than these is deﬁned as
'nonvalvular' and such patients were included in the trials.
Atrial ﬁbrillation with biological valves or after valve repair
constitutes a gray area; however, patients with these were
included in some trials on 'nonvalvular AF'.
5. Treatment with NOACs
5.1. Pharmacokinetics and drug–drug interactions
Treatment with NOACs needs consideration of their pharma-
cokinetics and interaction with concomitant medication and
co-morbidities. Table 5 summarizes the pharmacokinetic
proﬁle and Table 8 drug interactions of NOACs.
Absorption of NOACs is dependent on P-glycoprotein
(P-gp) and various drugs and food components are P-gp
modulators.78 The prodrug of dabigatran, dabigatran etex-
ilate, is a P-gp substrate and the bioavailability of dabigatran
varies with P-gp modulation. As dabigatran is primarily
excreted by the kidneys, P-gp inhibitors when administered in
cases of renal insufﬁciency may increase the bioavailability of
dabigatran. Many drugs used in AF are substrates for P-gp
(e.g., verapamil, dronedarone, amiodarone, and quinidine)
and may increase the bioavailability of both FIIa and FXa
inhibitors.79 NOACs should be avoided with concomitant
administration of strong inducers of P-gp and FXa are
contraindicated when used in combination with strong
inhibitors of both CYP3A4.80
Further details on speciﬁc interaction with NOACs are
presented in Table 8.5.2. Dose recommendations
Renal function is one of the most important criteria, which
affects the excretion of NOACs, and hence should be assessed
at least once a year for patients with normal or mild
impairment of renal function. Since most of the NOAC trials
used Cockroft Gault formula for calculating the creatinine
clearance of the patients, we recommend using the same.
Table 11 describes the dosing recommendations for NOACs.
5.3. Valvular heart disease in AF patients
It is reasonable to use NOACs in patients having mild to
moderate valvular disease. The current data also support the
use of NOACs in patients with bioprosthetic valves (not
mechanical valves).81
5.4. Monitoring anticoagulant effect
Anticoagulation therapy with warfarin needs dose adjustment
to achieve an INR of 2.0–3.0. Because of signiﬁcant inter- and
intrapatient variability of effective doses and various food and
drug interactions, regular anticoagulation monitoring is
required to keep all patients in the target INR range. When
a patient is started on warfarin, INR monitoring should be
performed daily for at least two days until the target INR is
achieved.82
NOACs do not require routine monitoring of coagulation.
However, quantitative assessment may be required to assess
drug exposure and anticoagulant effect in emergency situa-
tions. INR is not an effective option for monitoring antic-
oagulation in NOAC-treated patients. Given the direct
anticoagulant activity of NOACs, rapid onset/offset of antic-
oagulation effects, and relatively short half-lives, the exact
time of last dose intake relative to the time of blood sampling is
of prime importance.83
The activated partial thromboplastin time (aPTT) and the
prothrombin time (PT) may provide a qualitative assessment
for the presence of dabigatran and rivaroxaban, respectively.84
The relation between dabigatran and aPTT is curvilinear. In
patients undergoing chronic therapy with dabigatran, the
median peak aPTT was approximately 2-fold that of the
control. The median aPTT, 12 h after the last dose, was 1.5-fold
that of the control. If the aPTT level at trough (i.e., 12–24 h after
ingestion) still exceeds two times the upper limit of normal,
there may be a high risk of bleeding. Dabigatran has little effect
on the PT and INR assays. Therefore, they are not suitable for
quantitative assays.
The ecarin clotting time (ECT) assay provides a direct
measure of thrombin inhibition activity. Greater than 3-fold
elevation in the ECT value at trough is associated with the risk
of bleeding. Hemoclot® is a diluted thrombin time (dTT) test
developed with appropriate calibrators for interpretation in
the context of dabigatran use. When dabigatran is used with
twice daily dosing, the dTT measured at trough is associated
with an increased risk of bleeding.85
The choice of measurement methods for direct FXa
inhibitors is an anti-Xa assay. A number of in vitro and ex
vivo studies indicated that anti-Xa chromogenic assays are
Table 11 – Dosing recommendation of NOACs for thromboprophylaxis in atrial fibrillation.
Dabigatran (Pradaxa®)79 Rivaroxaban
(Xarelto®)58
Apixaban
(Eliquis®)
Edoxaban
(SAVYASA)65
Dosing recommendation 150 mg twice daily with or
without food
20 mg once daily with
evening meal
5 mg twice daily 60 mg once daily
Dose adjustment in
renal dysfunction
CrCl 15–30 ml/min
consider 75 mg twice daily
CrCl 30–50 ml/min
+ concomitant P-gp
inhibitor consider 75 mg
twice daily
CrCl 30–49 ml/min with
high risk of bleeding
consider 110 mg twice
daily
*75 mg approved in US
only
CrCl 30–50 ml/min
consider 15 mg once
daily
2.5 mg twice daily if any
2 of the following are
present: age ≥80 years,
body weight ≤60 kg,
serum creatinine
≥1.5 mg/dl
In case of CYP3A4 and P-
gp dual inhibitors
consider 2.5 mg twice
daily
CrCl 30–50 ml/min
consider 30 mg once
daily
Dose adjustment in
hepatic
impairment
In patients with moderate
hepatic impairment (Child
Pugh B) showed no
evidence of change in
exposure or
pharmacodynamics
Avoid use in patients
with Child–Pugh B
and C hepatic
impairment or with
any degree of hepatic
impairment
associated with
coagulopathy
Mild hepatic
impairment: no dose
adjustment needed
Moderate hepatic
impairment: no dosing
recommendation
available
Severe hepatic
impairment: avoid use
Avoid use in patients
with Child–Pugh B and C
hepatic impairment
Not recommended CrCl < 30 ml/min CrCl < 30 ml/min CrCl < 30 ml/min
CrCl, creatinine clearance; P-gp, P-glycoprotein; CYP, cytochrome P.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4S24more speciﬁc and sensitive than routine clotting test-based
assays. Commercial anti-Xa amidolytic assays are mainly
designed for measurement of anti-Xa activity of low molecular
weight heparins (LMWHs) and some may require modiﬁca-
tions for use with peak and trough levels of direct Xa inhibitors
in treated patient plasma. LMWH reference standard cannot
be recommended, as the mechanisms of action of the two
are different. Product-speciﬁc calibrators must be used for
accurate estimation of plasma level expressed in mass
concentration (e.g., mg/l). Factor Xa-inhibitors demonstrate
a concentration-dependent prolongation of PT. However, it is
subjected to huge variation because of differences in PT
reagents.86 At present, there are no US FDA approved assays
for the measurement of Factor Xa inhibitors. Currently, PT and
antifactor Xa chromogenic assays (where available) are consid-
ered appropriate for qualitative and quantitative measure-
ments of Factor Xa inhibitors, respectively. However, the
interpretation of these results is complicated, as no therapeutic
ranges exist.87,88 Also, usage of the appropriate calibrator
needs to be ensured if an antifactor Xa chromogenic assay is
to be performed (speciﬁcally, heparin calibrators are not to be
used).
Table 12 provides an overview of the anticoagulant
monitoring assay with particular application to the NOACs.
5.5. Overdoses
In terms of management of overdoses of NOACs, it is
important to distinguish between an overdose with and
without bleeding complications. Overdoses associated with
bleeding complications should be managed as discussed in the
section on management of complications. Coagulation tests
can help to determine the risk of bleeding and its severity.Activated charcoal may be considered to reduce absorption
of any NOAC.83 In addition, dialysis can be used to reverse the
effect of dabigatran. In absence of speciﬁc reversal agents, a
wait and see strategy is recommended since the half-life of
NOACs is relatively shorter.
5.6. Antidotes
Though speciﬁc antidotes for NOACs are currently unavail-
able, a few are under development. Aripazine (PER977), a small
synthetic molecule, and a potential universal reversal agent,
completely reversed the anti-Xa activity of rivaroxaban and
apixaban in a dose-dependent manner ex vivo in human
plasma. When administered to weight-matched rats over-
dosed with rivaroxaban, apixaban, and dabigatran, aripazine
decreased bleeding by >90% and the reduction was within the
normal range for un-anticoagulated rats in a standard tail
transaction bleeding model.89 Aripazine has undergone ﬁrst-
in-human studies in volunteers pretreated or untreated with
edoxaban. In this Phase I study, hemostasis was restored from
the anticoagulated state within 10–30 min after administra-
tion of 100 to 300 mg of Aripazine and was sustained for 24 h.90
Andexanet alpha (PRT064445), a truncated form of enzy-
matically inactive factor Xa, dose-dependently reversed the
inhibitory activity and corrected the prolongation of ex vivo
clotting time by factor Xa inhibitors.91 In phase II double-blind
studies, intravenous andexanet alpha (420 mg) neutralized the
antifactor Xa effects of apixaban and rivaroxaban by 91% and
53% (as compared to placebo), respectively.92,93 Both these
phase II studies have shown that anticoagulation returns to its
pretreatment state within several hours of the bolus infusion,
and thus, a constant infusion of this agent may be required for
reversing anticoagulation for a longer period of time.92,93
Table 12 – Anticoagulant monitoring assay.82–88
Parameter Description Dabigatran
(Pradaxa®)
Rivaroxaban
(Xarelto®)
Apixaban (Eliquis®) Edoxaban
(SAVYASA)
Time for peak effect – 2–3 hrs 2–4 hrs 3–4 hrs 1–2 hrs
Plasma trough level – 12–24 hrs after
ingestion
16–24 hrs after
ingestion
12–24 hrs after
ingestion
12–24 hrs after
ingestion
Activated partial
thromboplastin
time (aPTT)
Test for the intrinsic
system; measures
kininogen,
prekallikrein, XII, XI,
IX, VIII, X, V, and
thrombin
Qualitative
At trough: >2XULN
Suggest excess
bleeding risk
Not useful Not useful Not useful
Ecarin clotting
time (ECT)
Speciﬁc assay for
thrombin generation
Quantitative
At trough: ≥3 X ULN
Suggest excess
bleeding risk
Not affected Not affected Not affected
Prothrombin
time (PT)
Test of the extrinsic
pathway, measures
factor VII, X, V,
thrombin and
ﬁbrinogen
Not useful Qualitative Not useful Not useful
Thrombin time Functional test of
ﬁbrinogen
concentration and
ﬁbrin formation
Qualitative Not useful Not useful Not useful
Diluted TT (dTT) Uses the hemoclot
thrombin inhibitor
assay
Quantitative analysis Not useful Not useful Not useful
Antifactor Xa Measures factor X
activation directly
using a chromogenic
substrate
Not affected Quantitative; cut-off
values for bleeding or
thrombosis risk not
established
Quantitative; cut-off
values for bleeding or
thrombosis risk not
established
Quantitative; cut-off
values for bleeding or
thrombosis risk not
established
ULN, upper limit of normal.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 1 3 – s 3 4 S25Edoxaban 60 mg once daily was reversed by 52% after a bolus of
600 mg andexanet and by 73% after a bolus of 800 mg, each
followed by an infusion of 8 mg/min for 1 h.94
Idarucizumab, a humanized mouse monoclonal antibody
fragment (Fab), binds speciﬁcally to dabigatran with an afﬁnity
that is 350-fold greater than the afﬁnity of dabigatran for
thrombin. Rapid reversal of anticoagulant activity of dabiga-
tran was observed in rats administered an intravenous bolus
injection of idarucizumab. The ﬁrst-in-human, single-rising-
dose study found that idarucizumab achieved rapid peak
plasma concentration, had rapid elimination, had no endoge-
nous thrombin potential, and it did not affect any coagulation
parameters.95 The interim results of the RE-VERSE ADTM trial
are now available, and it was shown that idarucizumab
normalized the dTT and ECT test results in 88–98% of the
patients with a median maximum percentage reversal of 100%
(95% CI 100–100), and this effect was evident within minutes of
administration of the IV bolus 2.5 g followed by 2.5 g after
15 min – total 5 g of idarucizumab.96
Until these agents reach the market, the 'wait-and-see'
management can be advocated considering the relatively short
half-lives of NOACs in cases without bleeding complications.
5.7. Treatment of hypertrophic cardiomyopathy (HCM)
with AF using NOACs
Anticoagulation is indicated in HCM with AF irrespective of the
CHA2DS2-VASc score.
97 However, the choice of anticoagulationdepends on the patient proﬁle, as there is no data available to
support one anticoagulant over another.
5.8. Management of bleeding complications and reversal of
anticoagulation
Anticoagulant therapy carries the risk of bleeding, which may
be due to dosing errors, hemorrhagic diatheses, or emergency
medical procedures. Though the risk of major bleeding,
particularly intracranial bleeding and life-threatening bleed-
ing, was signiﬁcantly lower with the NOACs, as compared to
warfarin (Table 7), an effective plan is required for the
management of bleeding in a real-world clinical setting.
It is known that the anticoagulant effects of heparins and
VKAs can be reversed with protamine sulphate and prothrom-
bin supplementation, respectively.98 Administration of prot-
amine sulphate may be associated with the potential for
allergic response with ensuing hypotension and bronchocon-
striction.99 Reversal of the anticoagulant effect of VKAs with
oral or parenteral vitamin K has a slow onset (at least 12–24 h)
while fresh frozen plasma or coagulation factors may restore
coagulation more rapidly.98 In the absence of a speciﬁc
antidote for NOACs, the current recommendation for bleeding
management lacks the strength of clinical experience but
depends on expert opinion or standardized hospital protocols.
Table 13 summarizes the management strategy recom-
mended by this consensus statement that is also in alignment
with the commonly referred guidelines.
Table 13 – Possible measures to take in case of bleeding.98
Direct thrombin inhibitors (dabigatran) FXa inhibitors (apixaban, edoxaban, rivaroxaban)
Nonlife-threatening bleeding
 Record the dosage regimen and time of last dose intake
 Delay next dose or discontinue treatment as appropriate
 Consider factors inﬂuencing homeostasis (concomitant
antiplatelet medications) and those affecting plasma
concentrations (CYP3A4 and P-gp modulators)
Record the dosage regimen and time of last dose
intake
Delay next dose or discontinue treatment as
appropriate
Estimated time for normalization of hemostasis:
Normal renal function: 12–24 hrs
CrCl 50–80 ml/min: 24–36 hrs
CrCl 30–50 ml/min: 36–48 hrs
CrCl 30 ml/min: ≥48 hrs
Estimated time for normalization of hemostasis:
12–24 hrs
Standard supportive measures
 Mechanical compression
 Surgical hemostasis
 Fluid replacement (colloids if needed)
 RBC substitution if necessary
 Platelet substitution (in case of thrombocytopenia ≤60  109/L
or thrombopathy
 Fresh frozen plasma as plasma expander
Standard supportive measures
 Mechanical compression
 Surgical hemostasis
 Fluid replacement (colloids if needed)
 RBC substitution if necessary
 Platelet substitution (in case of thrombocytopenia
≤60  109/L or thrombopathy
 Fresh frozen plasma as plasma expander
 Tranexamic acid can be considered as an adjuvant
 Desmopressin can be considered in special cases (coagulopathy
or thrombopathy)
 Tranexamic acid can be considered as an adjuvant
 Desmopressin can be considered in special cases
(coagulopathy or thrombopathy)
 Maintain adequate diuresis
 Consider dialysis (preliminary evidence: 65% after 4 h)
 Charcoal hemoperfusion not recommended (no data)
Life-threatening bleeding
All of the above All of the above
PCC 25 U/kg (may be repeated once or twice) (but no clinical evidence) PCC 25 U/kg (may be repeated once or twice) (but no
clinical evidence)
aPCC (50 IE/kg; max 200 IE/kg/day): no strong data about additional
beneﬁt over PCC. Can be considered before PCC if available
a PCC 50 IE/kg; max. 200 IE/kg/day): no strong data
about additional beneﬁt over PCC. Can be considered
before PCC if available
Activated factor VII (rFVIIa; 90 mg/kg) no data about additional
beneﬁt + expensive (only animal evidence)
Activated factor VII (rFVIIa; 90 mg/kg) no data about
additional beneﬁt + expensive (only animal evidence)
CrCl, creatinine clearance; PCC, prothrombin complex concentrate; aPCC, activated Prothrombin complex concentrates.
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When switching between different anticoagulant therapies,
it is of paramount importance to maintain the anticoagula-
tion effect while minimizing the risk of bleeding at the same
time.
5.10. Switching to and from VKAs to NOAC
INR monitoring is needed when transitioning patients from
VKAs to a NOAC to avoid over anticoagulation. While switch-
ing from a NOAC to warfarin, consider bridging with a short-
acting parenteral agent or a lower dose of the NOAC.
5.11. Switching to and from parenteral anticoagulants to
NOACs
NOAC should be initiated up to 2 h before the next dose of the
parenteral agent when transitioning from a parenteral agent
to a NOAC. The prescribing information of each of the NOACs
describes the strategy for switching between these therapies.
Table 14 summarizes the transition between different treat-
ment regimens.5.12. Cardioversion or ablation in NOAC-treated patients
Interventions like ablation increase the bleeding risk and
require temporary discontinuation of the NOAC. In patients
scheduled to undergo ablation, it is reasonable to perform the
procedure 24 h after stopping the NOAC. It is recommended to
perform a transesophageal echocardiography before the
procedure, to rule out left atrial thrombi, as it is possible to
have a left atrial thrombus in spite of adequate oral antic-
oagulation. Pulmonary vein isolation (PVI) carries a risk of
serious bleeding. In practice, PVI is performed in VKA-treated
patients without the interruption of VKA treatment and such
an approach is associated with not only a reduction in
thromboembolic events, but also leads to less bleeding.
Comparable rates of thromboembolic events and bleeding
rates were observed with NOACs compared to uninterrupted
VKA. An individualized approach must be taken to decide on
changing patients to uninterrupted VKA, or uninterrupted
NOAC therapy, or of a well-planned cessation of NOAC. Studies
are ongoing to evaluate the use of uninterrupted NOAC
therapy before ablation. NOACs can be restarted 4 h after the
sheath removal provided there is no evidence of pericardial
effusion and adequate hemostasis has been achieved.78
Table 14 – Transition between anticoagulant regimens.
VKA to NOAC INR <2.0: immediate
INR 2.0–2.5: immediate or next day
INR >2.5: use INR and VKA half-life to estimate time to INR <2.5
Parenteral anticoagulant to NOAC:
Intravenous unfractioned heparin (UFH)
Low molecular weight heparin (LMWH)
Start once UFH discontinued (t½ = 2 h). May be longer in patients with
renal impairment
Start when next dose would have been given
NOAC to VKA Administer concomitantly until INR in appropriate range
Measure INR just before next intake of NOAC
Retest 24 h after last dose of NOAC
Monitor INR in ﬁrst month until stable values (2.0–3.0) achieved
NOAC to parenteral anticoagulant Initiate when next dose of NOAC is due
VKA, vitamin K antagonist; NOAC, nonvitamin K oral anticoagulants; INR, international normalized ratio.
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duration or AF of unknown duration, cardioversion should be
performed only after 3 weeks of effective oral anticoagulation
or if a transesophageal echocardiography (TOE) has ruled out
Left Atrial (LA) thrombi. If the TOE detects a LA thrombus, the
patient should not be subjected to cardioversion, as it can
increase the risk of embolization. If AF duration is of less than
48 h, it is recommended to treat the patient with LMWH,
supplement with TOE, and take a call to cardiovert the patient.
The patient can then be started on NOACs for at least 4 weeks,
irrespective of the patient's CHA2DS2-VASc score.
5.13. Planned/emergency surgical intervention
Patient characteristics (age, kidney function, previous bleeding
complications, and concomitant medication) and surgical
factors should be considered when deciding on the interrup-
tion and restart of NOAC drug. Interventions that carry no
clinically important risk of bleeding (e.g., dental procedures,
cataract, or glaucoma) can be performed at the trough
concentration of the NOAC and then restarted after 6 h. For
procedures involving minor risk of bleeding, it is recom-
mended to discontinue NOACs 24 h before the elective
procedure, provided the kidney functions normal. For proce-
dures involving a major risk of bleeding, cease the NOAC
treatment 48 h before the intervention. Though NOAC can be
resumed in 6–8 h after the intervention, for a few surgical
interventions, resuming full-dose anticoagulation within the
ﬁrst 48–72 h of the procedure may carry a bleeding risk that
outweighs the risk for cardioembolism. An emergency
intervention should be deferred, if possible, for at least 12 h
and ideally 24 h after the last dose of NOAC.
5.14. Management of acute coronary syndrome (ACS) and
AF
Coronary artery disease may coexist in approximately 20–30%
of patients with AF, which is an indication for continuous
antithrombotic treatment.100,101 A considerable number of
these patients are candidates for coronary revascularization to
reduce risk of recurrent ischemic events with percutaneous
coronary interventions (PCI), with stents implantation. Man-
agement of patients with NVAF and acute coronary syndrome
(ACS), either as a ST-elevation myocardial infarction (STEMI) or
as a non-ST elevation ACS (NSTE-ACS), is often challenging
given the multiplicity of therapeutic options.102A meta-analysis was performed to evaluate the efﬁcacy and
safety of adding NOAC (apixaban, dabigatran, rivaroxaban, and
ximelagatran) to single (aspirin) or dual (aspirin and clopidogrel)
antiplatelet therapy in patients presenting with ACS. When
compared with aspirin alone, the combination of an oral
anticoagulant and aspirin reduced the incidence of major
adverse cardiovascular events (MACEs) [HR and 95% CI 0.70;
0.59–0.84], but increased clinically signiﬁcant bleeding (HR: 1.79;
1.54–2.09). Compared to the dual antiplatelet therapy with
aspirin and clopidogrel, adding an oral anticoagulant decreased
the incidence of MACE modestly (HR: 0.87; 0.80–0.95), but
doubled the incidences of bleeding (HR: 2.34; 2.06–2.66).103
The EHRA 2013 guidelines also mention that a triple
therapy with dual antiplatelet agents and NOACs is associated
with at least doubling the risk of major bleeding.83 The WOEST
trial104 and the nationwide registry from Denmark105 reported
twice the number of bleeding episodes with triple therapy as
compared to double therapy with warfarin and clopidogrel
rather than aspirin. Hence, it cannot be said that NOACs
behave differently from VKAs.
When an AF patient on NOAC presents with ACS, the NOAC
treatment should be discontinued temporarily. The dual
antiplatelet therapy should be initiated immediately (only
aspirin in case of frail patients). In case of a STEMI, primary PCI
via radial approach is strongly recommended over ﬁbrinolysis.83
The recommendations for management post-ACS in AF
patients as per the ESC task force 2014 are depicted in Fig. 3.106
It suggests that the period of triple therapy (OAC plus aspirin
plus clopidogrel) should be as short as possible post-ACS. This
should be followed by OAC plus a single antiplatelet therapy
(preferably clopidogrel 75 mg/day, or as an alternative, aspirin
75–100 mg/day) and after a year, management should include
only OAC for patients with AF and stable vascular disease (i.e.,
no acute events or revascularization for >12 months, whether
coronary or peripheral artery disease). The OAC can be
adjusted-dose VKA or a NOAC.106 Dabigatran is the only NOAC
administered with clopidogrel and/or aspirin in AF patients
presenting with ACS at doses used for stroke protection.107
Other NOACs like apixaban (2.5 mg OD) and rivaroxaban
(15 mg OD) used in combination with clopidogrel and/or low-
dose aspirin were given as a dose adjustment based on patient
characteristics. No data are available indicating the beneﬁt of
rivaroxaban in ACS at the dose used for anticoagulation (20 mg
OD).108 Apixaban used in stroke prevention at a dose of 5 mg
BID in combination with aspirin plus clopidogrel, in an ACS
setting, was associated with excess bleeding.109
Fig. 3 – Management of acute coronary syndrome in atrial fibrillation.84
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anticoagulants
Intravenous recombinant tissue plasminogen activator (rtPA)
is an effective thrombolytic agent for acute ischemic stroke
and is approved when administered within 4.5 hours' timeFig. 4 – Stroke management in patients onwindow from onset of stroke symptoms.110 The American
Heart Association/American Stroke Association (AHA/ASA)
guideline111 allows the use of intravenous tissue plasminogen
activator in warfarin-treated patients, whose INR ≤1.7 are not
associated with an increased risk of symptomatic ICH.112 The
plasma half-lives of NOACs lie in the range of 8–17 h, and NOACs: (<4.5 h of symptom onset).84
Table 15 – Recommendations on the use of NOACs.83,113,115
, preferred; , may be considered; , not recommended.
* Edoxaban is not yet approved in India.
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48 h of the last administration of the NOAC. In case of
uncertainty about the last administered NOAC, coagulation
test (aPTT and PT) should be ordered. A prolonged aPTT in case
of dabigatran and a prolonged PT in case of factor Xa inhibitors
are indicators of in vivo anticoagulation; thus, thrombolytic
should not be administered. The EHRA 2013 guidelines
recommend that if NOACs have been administered within
48 h and coagulation tests are not available or are abnormal,
mechanical recanalization of occluded vessels may be
considered.83
Initiation or resumption of anticoagulation depends mainly
on the severity of stroke as assessed by the NIHSS (National
Institute of Health Stroke Scale) score. The thumb rule of 1-3-6-
12 day may be applied, wherein the anticoagulant treatment
may be resumed after a day in patients with transient ischemicattack; after 3 days in case of a small, nondisabling infarct;
after 6 days in patients with moderate stroke and not before 2
(or even 3) weeks in case of large infarcts/severe stroke.83 An
ESC 2012 focused update suggests considering dabigatran
150 mg BID in patients on rivaroxaban or apixaban treatment
who experience an ischemic stroke.113 Fig. 4 depicts the stroke
management ﬂowchart when the patient is on a NOAC.
Table 15 has detailed the recommendations of this consensus
statement for stroke prevention in AF patients.
6. Summary of recommendations
Several committees have reviewed the available data on
NOACs and provided recommendations to guide clinical
practice. EHRA 2013 offers a practical guide on various
Table 16 – Recommendations for stroke prevention in nonvalvular AF (ESC 2012 guidelines) 83,113
Category Recommendations
Stroke risk assessment  Stroke risk assessment should be based on CHA2DS2-VASc score
Bleeding risk assessment  Bleeding risk assessment should be based on HAS-BLED score
Renal function assessment  Regular assessment of renal function (by CrCl) is recommended in patients following
initiation of any NOAC, which should be done annually but more frequently in those with
moderate renal impairment where CrCl should be assessed 2–3 times per year
Antithrombotic therapy  Choice should be based on the absolute risk of stroke and bleeding and the net clinical
beneﬁt for a given patient
 Initiated for all patients with AF, except in those patients (both male and female) who are
at low risk (aged <65 years and lone AF), or with contraindications.
No antithrombotic therapy  For patients with a CHA2DS2-VASc score of 0 (i.e., aged <65 years with lone AF) with no risk
factors
 Female patients aged <65 and have lone AF (but still have a CHA2DS2-VASc score of 1 by
virtue of their gender)
CHA2DS2-VASc score ≥2  OAC therapy with adjusted-dose VKA (INR 2–3) or a direct thrombin inhibitor (dabigatran)
or an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban)
CHA2DS2-VASc score of 1  OAC therapy with adjusted-dose VKA (INR 2–3) or a direct thrombin inhibitor (dabigatran)
or an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) should be considered, based upon
an assessment of the risk of bleeding complications and patient references
Use of NOACs  Clinicians should administer dabigatran, rivaroxaban, or apixaban to patients who have
NVAF requiring anticoagulant medication and are at higher risk of intracranial bleeding
 Clinicians might offer apixaban to patients with NVAF and GI bleeding risk who require
anticoagulant medication
 Clinicians should offer dabigatran, rivaroxaban, or apixaban to patients unwilling or unable
to submit to frequent periodic testing of INR levels
NOACs contraindication  NOACs (dabigatran, rivaroxaban, and apixaban) are not recommended in patients with
severe renal impairment (CrCl <30 ml/min)
CrCl, creatinine clearance; NOACs, new oral anticoagulants; AF, atrial ﬁbrillation; OAC, oral anticoagulants; VKA, vitamin K antagonist; INR,
International normalized ratio; BID, twice daily; OD, once daily.
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update of the ESC guidelines also provides recommendation
for the prevention on stroke in NVAF and guidance for use of
NOACs.113 The American Academy of Neurology (2014)
provides guidance on the diagnosis of NVAF and discusses
therapeutic option to prevent stroke in NVAF.114 In view of the
observations that individuals with Asian ethnicity are at a
disproportionately higher risk of stroke and are more prone to
warfarin-associated hemorrhages, Sabir et al. review the use of
NOACs in the management of AF in Asian populations.115
Table 16 summarizes the important recommendations on
stroke prevention as suggested by various guidelines in
patients with AF using NOACs.
The recommendations made by this consensus statement
are summarized in Table 15. For patients with NVAF, direct
thrombin inhibitors (Dabigatran) or factor Xa inhibitors
(rivaroxaban or apixaban) may be preferred to all patients
and specially those who are unable to maintain the target INR
levels with warfarin. Similarly, for patients who are unable or
unwilling to submit to the frequent periodic testing of INR
levels, dabigatran, rivaroxaban, or apixaban may be offered.
Edoxaban may be included in any upcoming guidelines, and as
more clinical experience accumulates, the management of
stroke prevention in NVAF may see more reﬁned recommen-
dations.
7. Future scope for research
There are limited data on the community prevalence of AF and
focused studies are needed to delineate the rural and urbanprevalence of AF separately. The utility of the CHA2DS2-VASc
and HAS-BLED scoring in Indian populations has not been
studied and further studies focusing on validating these scores
in an Indian population are required. As AF patients in India
often have a rheumatic valvular component, the utility of
NOACs in this population without mechanical valves needs to
be studied in detail in an Indian setting. Different studies are
ongoing (currently recruiting), including use of NOAC in
special situations like post-PCI (RE-DUAL PCI and AUGUSTUS),
postablation (RE-CIRCUIT and VENTURE AF), and other
conditions like postcardioversion and in CKD patients. The
consensus statement will be updated as and when the results
of these trials become available.
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